Stock Events

Stock Events

Immunocore 

€26.60
31
-€0.60-2.21% 20:46 Today

Statistics

Day High
27.2
Day Low
26.4
52W High
35.4
52W Low
23.4
Volume
-
Avg. Volume
-
Mkt Cap
1.37B
P/E Ratio
-
Dividend Yield
-
Dividend
-

Financials

-8.89%Profit Margin
Unprofitable
2020
2021
2022
2023
2024
2025
340.18MRevenue
-30.25MNet Income

Analyst Ratings

$46.79Average Price Target
The highest estimate is ⁦75.88⁩.
From 3 ratings within the last 6 months. This is not an investment recommendation.
Buy
67%
Hold
33%
Sell
0%

People Also Follow

This list is based on the watchlists of people on Stock Events who follow 6YG.STU. It's not an investment recommendation.
Microsoft
4
MSFT
Tesla
4
TSLA
NVIDIA
4
NVDA
Schwab US Dividend Equity
4
SCHD

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
Gilead Sciences
GILD
Mkt Cap211.7B
Gilead Sciences, through its acquisition of Kite Pharma, competes in the cell therapy space for oncology, overlapping with Immunocore's cancer treatments.
Novartis
NVS
Mkt Cap303.67B
Novartis offers CAR-T cell therapies for cancer, directly competing with Immunocore's immuno-oncology approaches.
Bristol-Myers Squibb
BMY
Mkt Cap127.71B
Bristol Myers Squibb, with its acquisition of Celgene, has a strong presence in immuno-oncology, competing in the same space as Immunocore.
Allogene Therapeutics
ALLO
Mkt Cap407.68M
Allogene Therapeutics is focused on allogeneic CAR-T therapies for cancer, which competes with Immunocore's approach to cancer treatment.
CRISPR Therapeutics
CRSP
Mkt Cap4.97B
CRISPR Therapeutics is engaged in gene editing for cancer therapies, which could compete with Immunocore's cell-based cancer treatments.

About

Immunocore Holdings PLC is a commercial-stage biotechnology company. Using its ImmTAX platform, the company is developing a deep pipeline in multiple therapeutic areas, including clinical stage programs in oncology and infectious disease, pre-clinical programs in autoimmune disease, and earlier pre-clinical programs across three therapeutic areas. The company's main product, KIMMTRAK, is used for the treatment of unresectable or metastatic uveal melanoma (mUM). The other drug candidates in its pipeline include Brenetafusp, IMC-P115C, IMC-T119C, IMC-R117C, IMC-S118AI, IMC-U120AI, and others, being developed as a potential treatment for various oncology, infectious, and autoimmune diseases.
Show More
CEO
Bahija Jallal
Employees
524
Country
United Kingdom
ISIN
US45258D1054
WKN
000A2QNWU

Listings

STU
DE
6YG.STU
MU
DE
6YG.MU
XNAS
US
IMCR
F
DE
6YG.F

0 Comments

Share your thoughts

FAQs

What is Immunocore stock price today?▼
The current price of 6YG.STU is €26.60 EUR — it has decreased by -2.21% in the past 24 hours. Watch Immunocore stock price performance more closely on the chart.
What is Immunocore stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on Boerse Stuttgart exchange Immunocore stocks are traded under the ticker 6YG.STU.
Is Immunocore stock price growing?▼
6YG.STU stock has fallen by -4.32% compared to the previous week, the month change is a +1.53% rise, over the last year Immunocore has showed a -6.34% decrease.
What is Immunocore market cap?▼
Today Immunocore has the market capitalization of 1.37B
What is Immunocore revenue for the last year?▼
Immunocore revenue for the last year amounts to 340.18M EUR.
What is Immunocore net income for the last year?▼
6YG.STU net income for the last year is -30.25M EUR.
How many employees does Immunocore have?▼
As of November 2, 2026, the company has 524 employees.
In which sector is Immunocore located?▼
Immunocore operates in the Health & Wellness sector.
When did Immunocore complete a stock split?▼
Immunocore has not had any recent stock splits.
Where is Immunocore headquartered?▼
Immunocore is headquartered in OXFORDSHIRE, United Kingdom.